PLEC has been identified as a promising biomarker and therapeutic target in pancreatic adenocarcinoma (PAAD) (Ge et al., 2024), while amplification of NSB1 has been shown to drive the pathobiology of uveal melanoma (UM) (Banimohammad et al., 2025). Here, PLEC is linked to uveal melanoma.